Oncolytics Biotech Inc. Announces FDA Feedback on REO‑033 Study

What Happened On August 18, 2026, Oncolytics Biotech Inc. announced via press release (filed on Form 8‑K) that it received feedback from the U.S. Food and Drug Administration (FDA) related to the planned pivotal Part B expansion of its REO‑033 colorectal cancer study and other planned study design elements. The company disclosed the announcement under Item 8.01 (Other Events) of the 8‑K.

Key Details

• Filing date: August 18, 2026 (Form 8‑K, Items 8.01 and 9.01).
• Subject: FDA feedback on the planned pivotal Part B expansion of the REO‑033 colorectal cancer study and other study design elements.
• Exhibits: Exhibit 99.1 = Press Release dated August 18, 2026; Exhibit 104 = Interactive XBRL cover page.
• Signature: Report signed by Kirk Look, Chief Financial Officer, dated August 18, 2026.
• The 8‑K reports the announcement of FDA feedback but does not present clinical data or a regulatory decision in the filing itself.

Why It Matters FDA feedback on a planned pivotal expansion and study design is a key regulatory milestone for a clinical-stage biotech. For investors, this update signals that Oncolytics is engaging with regulators on the design of a potentially pivotal colorectal cancer trial (REO‑033), which can affect future trial plans, endpoints and regulatory strategy. Investors should look for follow-up disclosures with detailed FDA guidance, protocol amendments, timelines, or any changes to enrollment or endpoints.